Genetic Rx panel on gene therapy regulatory strategies led by Renova Therapeutics CEO and Co-founder
SAN DIEGO, Dec. 5, 2017 /PRNewswire/ -- Renova™ Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced today that the company's CEO and Co-founder, Jack W. Reich, Ph.D., will moderate a gene therapy panel at Genetic Rx, a networking conference of the Boston Biotech Conferences series. The conference will be held at Harvard Medical School on December 7.
Genetic Rx is focused on the emergence of new genetic medicines and therapies, as well as the treatment of patients with rare and ultra-rare genetic diseases. Dr. Reich will moderate a panel entitled "Regulatory Strategies for Gene Therapy Products" to elucidate the regulations surrounding development and approval of this type of medicine.
"I look forward to leading the discussion on the regulatory approach for gene therapies," says Dr. Reich. "There are many advantages to gene therapies over small-molecule drugs – and the specific regulatory process that accompanies the development of a gene therapy product."
A pioneer in the field, Dr. Reich is well-versed in the regulatory aspects of developing gene therapies. Throughout his career, Dr. Reich has had significant interactions with regulatory bodies and has been responsible for regulatory approval and successful introduction of a broad range of new drugs.
Dr. Reich's expertise in the regulatory field began early in his career. His Ph.D. dissertation was the first in the area of international drug development and registration. Dr. Reich conceived of a system of harmonization of testing and regulatory requirements for new drugs to replace the then-current system of repetitive testing in each country to satisfy local registration requirements. This new approach became a roadmap for what is now the standard approach to testing and registering new medicines. Subsequently, his experience leading clinical-stage gene therapy companies led to an in-depth understanding of the accompanying regulatory process.
The Genetic Rx panel will feature John Maslowski, President and CEO of Fibrocell Science, and Jennifer Spinella, Executive Vice President of Regulatory Affairs and Quality Assurance at Renova Therapeutics. This year's Genetic Rx conference is sponsored by Brammer Bio and the BioPharma Executive Council.
About Renova Therapeutics
Renova Therapeutics is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. The first indications the company is pursuing are gene therapy treatments for heart failure and type 2 diabetes, two of the most common and devastating chronic diseases in the world. The company's lead product candidate, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in millions of patients with heart failure. The company's product pipeline also includes a groundbreaking gene therapy in preclinical stage for sufferers of type 2 diabetes, as well as a peptide infusion therapy for the treatment of acute decompensated heart failure. Renova Therapeutics was founded in 2009 and is led by an experienced management team in biopharmaceuticals and gene therapy. For additional information about the company, please visit www.renovatherapeutics.com.
SOURCE Renova Therapeutics
Share this article